{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:51:14Z","timestamp":1775256674431,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijgc.2025.102122","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:50:27Z","timestamp":1755845427000},"page":"102122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment tolerability associated with carboplatin dose based on actual versus adjusted body weight in patients with a body mass index \u226525 kg\/m2 with advanced ovarian cancer"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5651-2212","authenticated-orcid":false,"given":"Matthew","family":"Savas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Gamvroulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-5780","authenticated-orcid":false,"suffix":"II","given":"T Joseph","family":"Mattingly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa L.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2025.102122_bib1","unstructured":"Ovarian cancer\u2014Cancer Stat Facts. Surveillance, Epidemiology, and End Results Program. Accessed July 29, 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"10.1016\/j.ijgc.2025.102122_bib2","unstructured":"Cancer Ovarian. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). NCCN.org. Accessed July 23, 2023. https:\/\/www.nccn.org\/patients."},{"issue":"26","key":"10.1016\/j.ijgc.2025.102122_bib3","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ijgc.2025.102122_bib4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102122_bib5","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102122_bib6","unstructured":"Appendix B. Carboplatin Dosing in Adults. NCCN Chemotherapy Order Templates (NCCN Templates\u00ae). Accessed July 16, 2023. https:\/\/www.nccn.org\/docs\/default-source\/clinical\/order-templates\/appendix_b.pdf?sfvrsn=6286822e_10."},{"key":"10.1016\/j.ijgc.2025.102122_bib7","unstructured":"GOG-0262\/ACRIN 6695. Appendix V: Carboplatin Dose Calculation Instructions. Gynecologic Oncology Group; June 20, 2011. Accessed July 16, 2023."},{"issue":"13","key":"10.1016\/j.ijgc.2025.102122_bib8","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"30","author":"Griggs","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102122_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2008.02.023","article-title":"Carboplatin dosing in obese women with ovarian cancer: a gynecologic oncology group study","volume":"109","author":"Wright","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102122_bib10","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102122_bib11","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/s41416-023-02259-1","article-title":"Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer","volume":"128","author":"Martin","year":"2023","journal-title":"Br J Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25012423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25012423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:40:25Z","timestamp":1762209625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25012423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1048891X25012423"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102122","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment tolerability associated with carboplatin dose based on actual versus adjusted body weight in patients with a body mass index \u226525 kg\/m2 with advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"102122"}}